Introduction
Macular Diseases
Subliminal laser therapy: a macular treatment

There remains an unmet need in the treatment of macular diseases. Increasing evidence demonstrates SubLiminal laser therapy to be safe and effective for macular conditions such as DME and CSC.

A macular treatment

Treatment guidelines

Testimonials

Clinical data
Peripheral Retinal Diseases
Subliminal laser therapy: not a peripheral treatment

Several studies demonstrate that retinal destruction was required to control the neovascularization process in PDR. For peripheral conditions Multispot laser photocoagulation should be favored.

Multispot for PRP treatment

Treatment guidelines

Testimonials

Clinical data
Media Library

Archives: PDF

Central Serous Chorioretinopathy: Can it be treated without Visudyne?

03/05/2022

Given the difficulty of obtaining verteporfin for chronic CSCR, it is worth considering subthreshold laser therapy as an alternative given its comparable efficacy and practical advantages. We know that the prognosis for this disease depends on the level of disease progression, so a therapeutic option that allows for an undelayed treatment is extremely interesting.

Laser Remains an Effective Option for DME and CSCR Treatments

16/12/2021

Diabetic macular edema (DME) is the leading cause of irreversible visual loss in the diabetic population. Laser plays a very important role in the treatment of DME despite the use of anti-VEGF agents, said Dr. Victor Chong, consultant ophthalmic surgeon at London Medical, United Kingdom, during a symposium at the recently held APAO 2021 Virtual.

The Argument for Laser in 2021

30/09/2021

When discussing treatment for macular pathologies like diabetic macular edema (DME) and central serous chorioretinopathy (CSCR), injection burden is a term that often appears.

Formation of the Subthreshold Ophthalmic Laser Society

30/09/2021

Laser photocoagulation has been used in ophthalmology for many years. During photocoagulation, a continuous wave of energy is delivered to the target tissue throughout the entire duration of the laser pulse.

SubLiminal Laser Therapy for CSC

25/08/2021

Central serous chorioretinopathy (CSC) is a common posterior pole disease with a high recurrence rate and etiology. Its pathogenesis is ambiguous; however, it is characterized by the decompensation of the retinal pigment epithelium (RPE) and usually results in serous detachment of neuroretina, serous pigment epithelium detachment (PED), and RPE atrophy.

Retina Treatment: Subliminal Treatment Procedure

25/02/2021

Retina Treatment: Subliminal Treatment Procedure by Victor CHONG, MD (UK), Royal Free London NHS Foundation Trust, Optegra Eye Hospital, Central London

Multispot Treatment Guidelines

13/02/2021

Easyret Treatment Guidelines: Multispot mode

SubLiminal Laser for Center-Involving Diabetic Macular Edema

20/12/2020

Diabetic retinopathy (DR) is a major microvascular complication of diabetes. It is estimated that by 2030, nearly 200 million people will be affected by this disease. During this period, visionthreatening DR will increase from 37 million to 56 million people globally. Center-involved diabetic macular edema (CI-DME) is the most common cause of decreased visual acuity in DR patients, affecting more than 750,000 patients in the United States alone.

Safe and Effective Laser Therapies: Targeting Retinal Diseases Amidst COVID-19

28/09/2020

In this time of uncertainty, one thing is certain (at least in ophthalmology): Retinal pathologies are not going anywhere. In fact, chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR) are thought to be causing more concerns during this period of worldwide lockdown and social distancing.

An Exciting Journey in SubLiminal Laser Treatment Therapy for DME

20/07/2020

DME is one of the most common causes of sightthreatening retinopathy for people with diabetes, which currently affects more than 30 million people worldwide. As the prevalence of diabetes and vision diseases related to diabetes continues to rise, so does the burden it creates on health care systems.

Quantel Medical & Ellex, 2 brands of Lumibird Medical, united with 1 objective: develop cutting-edge technologies for the diagnosis and treatment of dry eye and leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.

More info

"*" indicates required fields

Name

First Last

The information collected through this form is recorded and transmitted to the relevant QUANTEL MEDICAL departments and enables us to send you any reply to a request via the contact form. The legal basis for the processing is consent. The data collected are kept for 3 years in digital format and are only transmitted to QUANTEL MEDICAL’s internal departments as well as to our distributors and subsidiaries. You have a right to access, rectify, contest, limit the processing of and erase data. For more information on the use of your data and your rights resulting from the amended French Data Protection Act and the GDPR, please consult our data protection policy or contact our Data Protection Officer at rgpd@quantelmedical.fr.

Country*

Personal data compliance

I agree to my personal data being used by QUANTEL MEDICAL to send me marketing information about QUANTEL MEDICAL’s new products, events or offers (mailings).

I do not agree to my personal data being used by QUANTEL MEDICAL to send me marketing information about QUANTEL MEDICAL’s new products, events or offers (mailings).

Email*

For more informations on how Quantel Medical uses your data, please see our Terms and conditions.

Data policy

Site plan – Terms & Conditions – Privacy policy – Cookie policy